Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Deffered Revenue (2017 - 2018)

Puma Biotechnology (PBYI) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $5.8 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deffered Revenue rose 7.57% year-over-year to $5.8 million, compared with a TTM value of $5.8 million through Dec 2018, up 7.57%, and an annual FY2018 reading of $5.8 million, up 7.57% over the prior year.
  • Non-Current Deffered Revenue was $5.8 million for Q4 2018 at Puma Biotechnology, down from $5.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $5.9 million in Q3 2018 and bottomed at $5.4 million in Q4 2017.